AstraZeneca (AZN)
AstraZeneca Statistics
Share Statistics
AstraZeneca has 6.2B shares outstanding. The number of shares has increased by 0.02% in one year.
| Shares Outstanding | 6.2B |
| Shares Change (YoY) | 0.02% |
| Shares Change (QoQ) | 0.02% |
| Owned by Institutions (%) | 16.55% |
| Shares Floating | 6.2B |
| Failed to Deliver (FTD) Shares | 30 |
| FTD / Avg. Volume | < 0.01% |
Short Selling Information
The latest short interest is -, so null% of the outstanding shares have been sold short.
| Short Interest | - |
| Short % of Shares Out | null% |
| Short % of Float | null% |
| Short Ratio (days to cover) | null |
Valuation Ratios
The PE ratio is 28.95 and the forward PE ratio is 13.28. AstraZeneca's PEG ratio is 1.53.
| PE Ratio | 28.95 |
| Forward PE | 13.28 |
| PS Ratio | 3.77 |
| Forward PS | 5.8 |
| PB Ratio | 4.99 |
| P/FCF Ratio | 27.99 |
| PEG Ratio | 1.53 |
Enterprise Valuation
AstraZeneca has an Enterprise Value (EV) of 126.45B.
| EV / Sales | 2.34 |
| EV / EBITDA | 7.39 |
| EV / EBIT | 10.66 |
| EV / FCF | 17.38 |
Financial Position
The company has a current ratio of 0.93, with a Debt / Equity ratio of 0.74.
| Current Ratio | 0.93 |
| Quick Ratio | 0.74 |
| Debt / Equity | 0.74 |
| Debt / EBITDA | 1.76 |
| Debt / FCF | 4.14 |
| Interest Coverage | 5.74 |
Financial Efficiency
Return on Equity is 17.25% and Return on Invested Capital is 10.3%.
| Return on Equity | 17.25% |
| Return on Assets | 6.76% |
| Return on Invested Capital | 10.3% |
| Revenue Per Employee | $573.41K |
| Profits Per Employee | $74.6K |
| Employee Count | 94,300 |
| Asset Turnover | 0.52 |
| Inventory Turnover | 1.93 |
Taxes
| Income Tax | 1.65B |
| Effective Tax Rate | 18.99% |
Stock Price Statistics
The stock price has increased by -1.21% in the last 52 weeks. The beta is 0.25, so AstraZeneca's price volatility has been higher than the market average.
| Beta | 0.25 |
| 52-Week Price Change | -1.21% |
| 50-Day Moving Average | 73.24 |
| 200-Day Moving Average | 73.97 |
| Relative Strength Index (RSI) | 40.79 |
| Average Volume (20 Days) | 6.16M |
Income Statement
In the last 12 months, AstraZeneca had revenue of 54.07B and earned 7.04B in profits. Earnings per share was 4.53.
| Revenue | 54.07B |
| Gross Profit | 43.87B |
| Operating Income | 10B |
| Net Income | 7.04B |
| EBITDA | 17.12B |
| EBIT | 10.43B |
| Earnings Per Share (EPS) | 4.53 |
Balance Sheet
The company has 5.49B in cash and 30.11B in debt, giving a net cash position of -24.63B.
| Cash & Cash Equivalents | 5.49B |
| Total Debt | 30.11B |
| Net Cash | -24.63B |
| Retained Earnings | 3.16B |
| Total Assets | 104.03B |
| Working Capital | -2.04B |
Cash Flow
In the last 12 months, operating cash flow was 11.86B and capital expenditures -4.59B, giving a free cash flow of 7.28B.
| Operating Cash Flow | 11.86B |
| Capital Expenditures | -4.59B |
| Free Cash Flow | 7.28B |
| FCF Per Share | 4.68 |
Margins
Gross margin is 81.12%, with operating and profit margins of 18.5% and 13.01%.
| Gross Margin | 81.12% |
| Operating Margin | 18.5% |
| Pretax Margin | 16.07% |
| Profit Margin | 13.01% |
| EBITDA Margin | 31.66% |
| EBIT Margin | 18.5% |
| FCF Margin | 13.45% |
Dividends & Yields
AZN pays an annual dividend of $2.52, which amounts to a dividend yield of 2.07%.
| Dividend Per Share | $2.52 |
| Dividend Yield | 2.07% |
| Dividend Growth (YoY) | 6.6% |
| Payout Ratio | 112.22% |
| Earnings Yield | 3.45% |
| FCF Yield | 7.14% |
Analyst Forecast
The average price target for AZN is $90, which is 33.3% higher than the current price. The consensus rating is "Buy".
| Price Target | $90 |
| Price Target Difference | 33.3% |
| Analyst Consensus | Buy |
| Analyst Count | 6 |
Stock Splits
The last stock split was on Jul 27, 2015. It was a forward split with a ratio of 2:1.
| Last Split Date | Jul 27, 2015 |
| Split Type | forward |
| Split Ratio | 2:1 |
Scores
| Altman Z-Score | 4.88 |
| Piotroski F-Score | 7 |